Please note some content on this site is no longer supported on Internet Explorer 8, we recommend you upgrade your browser
ONCOS-102 is a purposefully engineered human serotype 5 adenovirus optimized to induce systemic anti-tumor T cell response in cancer patients.
In order to make ONCOS-102 even more powerful, it includes three engineered characteristics:
Local ONCOS-102 treatment induces a unique, systemic anti-tumor immune response in patients. The mechanism of action has been established by systemically studying samples collected from patients before and after treatment with ONCOS-102.
Activated T cells attack and kill tumor cells expressing the specific antigens. The effect is systemic.
Investor Email Alerts